Top

US registers new COVID-19 medicine in accelerated mode

US registers new COVID-19 medicine in accelerated mode
US registers new COVID-19 medicine in accelerated mode

The United States has registered the RegN-COV2 medicine, made by Regeneron Pharmaceuticals, in an accelerated mode on November 21.

The medicine, or antibody ‘cocktail’, will be used for treating patients from the age of 12 in the US.

Reports say 799 patients took part in the studies.

The New York Times says that the US government allocated 500 mln USD for further development of REGN-COV2.

The medication is efficient in the initial phase of the infection.

It was used for providing US President Trump with treatment in October.

If you find out orphographic mistake in the text, please select mistaken part of the text and press Ctrl + Enter.

Last added

Latest news



orphus_system